stockrow
Friday 6 November 2026
Export CYTK’s income statement to Excel — free account
Cytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.4%
- Free cash flow
- −6.73%
- Total debt
- +6.01%
Quarter to September 2026, against a year earlier
53.84
1.71
−3.08%
Follow CYTK
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 1 | 2 | 2 |
+8 more TTM periods Free account |
| 184.71% | 329.76% | 151.81% | 197.47% | ||
| (47.70%) | (56.76%) | (65.39%) | (55.55%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(85.50%) | (80.83%) | (114.79%) | (98.90%) | |
Average Days of Receivables |
109.18 | 131.78 | 23.55 | 73.65 | |
Free Cash Flow per Share |
(4.23) | (4.40) | (4.45) | (4.45) | |
Free Cash Flow |
(588.58) | (580.71) | (548.92) | (534.82) | |
Capital Expenditures |
(16.61) | (25.26) | (25.07) | (24.81) | |
| Other line items | |||||
Cash ROIC |
(30.02%) | (27.15%) | (47.55%) | (38.76%) | |
Accounts Receivable Turnover |
6.35 | 4.12 | 23.94 | 5.12 | |
Accounts Payable Turnover |
0.51 | 0.68 | 0.44 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
770.73 | 599.08 | 1,063.16 | 0.00 | |
Days of Inventory on Hand |
23.96 | 11.10 | 6.63 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
355.67% | 592.52% | 390.58% | 472.55% | |
Selling, General and Administrative Expense of Revenue |
365.57% | 547.47% | 313.56% | 322.89% | |
Share Based Compensation of Revenue |
115.92% | 188.13% | 112.58% | 127.54% | |
Interest Coverage |
(5.17) | (5.67) | (5.60) | (5.89) | |
Operating CF/Net income |
0.74 | 0.62 | 0.63 | 0.65 | |
Depreciation/Fixed assets |
0.18 | 0.16 | 0.14 | 0.13 | |
Capex/Depreciation |
(1.23) | (2.01) | (2.24) | (2.45) | |
Revenue per Share |
0.81 | 0.51 | 0.86 | 0.73 | |
Operating CF per Share |
(4.11) | (4.21) | (4.25) | (4.25) | |
Capex per Share |
(0.12) | (0.19) | (0.20) | (0.21) | |
Capex to Sales |
0.15 | 0.37 | 0.24 | 0.28 |
Columns are period end dates · fundamentals updated 6 Nov 2026